Related Experiment Video
Updated: Oct 12, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
Perspectives on SARS-CoV-2 Main Protease Inhibitors
Kaifu Gao1, Rui Wang1, Jiahui Chen1
1Department of Mathematics, Michigan State University, East Lansing, Michigan 48824, United States.
Abstract:
The main protease (Mpro) plays a crucial role in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication and is highly conserved, rendering it one of the most attractive therapeutic targets for SARS-CoV-2 inhibition. Currently, although two drug candidates targeting SARS-CoV-2 Mpro designed by Pfizer are under clinical trials, no SARS-CoV-2 medication is approved due to the long period of drug development. Here, we collect a comprehensive list of 817 available SARS-CoV-2 and SARS-CoV Mpro inhibitors from the literature or databases and analyze their molecular mechanisms of action. The structure-activity relationships (SARs) among each series of inhibitors are discussed. Additionally, we broadly examine available antiviral activity, ADMET (absorption, distribution, metabolism, excretion, and toxicity), and animal tests of these inhibitors. We comment on their druggability or drawbacks that prevent them from becoming drugs. This Perspective sheds light on the future development of Mpro inhibitors for SARS-CoV-2 and future coronavirus diseases.
Insights
This study reviews 817 SARS-CoV-2 main protease inhibitors, analyzing their mechanisms, activity, and druggability. It highlights challenges and future directions for developing effective COVID-19 treatments targeting the viral Mpro.
Area of Science:
- * Virology and Drug Discovery
- * Medicinal Chemistry and Pharmacology
Background:
- * The SARS-CoV-2 main protease (Mpro) is essential for viral replication and a key therapeutic target.
- * Current drug development for COVID-19 is lengthy, with no approved medications yet.
Purpose of the Study:
- * To compile and analyze a comprehensive list of SARS-CoV-2 and SARS-CoV Mpro inhibitors.
- * To evaluate their molecular mechanisms, structure-activity relationships (SARs), antiviral activity, and druggability.
Main Methods:
- * Literature and database compilation of 817 Mpro inhibitors.
- * Analysis of molecular mechanisms, SARs, antiviral data, ADMET properties, and animal study results.
Main Results:
- * Detailed review of 817 SARS-CoV and SARS-CoV-2 Mpro inhibitors.
- * Discussion of SARs, antiviral efficacy, ADMET profiles, and animal model data.
- * Identification of druggability and limitations for potential therapeutics.
Conclusions:
- * The study provides a comprehensive overview of existing Mpro inhibitors.
- * It offers insights into the development of novel inhibitors for SARS-CoV-2 and future coronavirus diseases.
Related Concept Videos
Subviral Agents
Conjugated Proteins
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Enzyme Inhibition
Dipeptidyl Peptidase 4 Inhibitors
Antimicrobial Effectiveness

